scholarly journals Alzheimer’s disease with an early debut

2019 ◽  
pp. 10-16
Author(s):  
N. N. Koberskaya ◽  
N. A. Kovalchuk
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Side Effects ◽  
Early Onset ◽  
Clinical Case ◽  
Limited Spectrum

The article reviews a clinical case of Alzheimer’s disease (AD) with early onset. This case study shows current approaches to the diagnosis of this form of AD and the management of this group of patients. It is reasonable to use Acathinol memantin in patients with early onset of AD. The drug is characterized by a minimal number of side effects and a limited spectrum of contraindications.

scholarly journals A Case of Early-Onset Alzheimer's Disease with MAPT P301L Mutation and Literature Review

2022 ◽  
Author(s):  
Jia Li ◽  
Jingqi Feng ◽  
Hang Su ◽  
Jiajun Chen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Early Onset ◽  
Clinical Case ◽  
Heterozygous Mutation ◽  
Mapt Gene ◽  
Early Onset Alzheimer’S Disease ◽  
Disease Related Genes ◽  
P301l Mutation

Abstract Background: Early-onset Alzheimer's disease is defined as Parkinson's disease that begins at an age of 65 or younger. Currently, among the reports on early-onset Alzheimer's disease related genes, mutations of APP, PSEN1 and PSEN2 genes are relatively common, However, the mutation of MAPT P301L causes early-onset Alzheimer's disease, which has not been reported so far. Case report: We have found a clinical case of a 30-year-old male who suddenly developed cognitive impairment and progressed rapidly within 2 years, leaving him unable to take care of himself. The patient underwent examinations of blood and cerebrospinal fluid routine, biochemistry and immunoassay, as well as imaging examinations of MRI, FDGPET and PIBPET. PIB-PET indicated diffuse heterogeneous radionuclivity in cerebral cortex, and positive PIB imaging was considered. Sequencing results suggested that there was a heterozygous mutation in the MAPT gene of the patient, which was located in Chr17-44087755, and c.902C>T. Conclusion: We speculated that EOAD of this patient may be related to the P301L mutation on MAPT.

scholarly journals Early onset Alzheimer’s disease – a case study

2020 ◽  
pp. 1-7
Author(s):  
Beata Łabuz-Roszak ◽  
Magdalena Torbus-Paluszczak ◽  
Janusz Becelewski ◽  
Michał Becelewski ◽  
Paweł Dobrakowski ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Onset ◽  
Early Onset Alzheimer’S Disease

Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer’s Disease

2018 ◽  
Author(s):  
Adam P. Mecca ◽  
Rajesh R. Tampi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Side Effects ◽  
Adverse Events ◽  
Atypical Antipsychotic ◽  
Clinical Case ◽  
Atypical Antipsychotics ◽  
Antipsychotic Drugs ◽  
Multicenter Trial ◽  
Antipsychotic Treatment

This chapter provides a summary of the Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s disease (CATIE-AD), a multicenter trial that investigated whether atypical antipsychotics are an effective treatment for psychosis, aggression, or agitation in outpatients with Alzheimer’s disease. The chapter briefly reviews the study design, as well as implications and limitations. A relevant clinical case concludes the chapter. In summary, atypical antipsychotic use for up to 36 weeks did not lead to clinical improvement based on time to discontinuation, or symptom reduction. Risk of discontinuation due to adverse events and side-effects with worse with antipsychotic treatment compared to placebo. In patients with psychosis, agitation, or aggression due to Alzheimer’s disease, the efficacy of atypical antipsychotics is questionable and their use comes with considerable risks of side effects and adverse events.

The Applicability and Effect of EMDR in a Patient With a Mild Stage of Alzheimer's Disease

2019 ◽  
Vol 13 (1) ◽  
pp. 51-60
Author(s):  
Martje van der Wielen ◽  
Hanneke Robben ◽  
Ruth E. Mark
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Case ◽  
Stress Disorder ◽  
Life Experiences ◽  
Traumatic Memory ◽  
Clinical Case Study ◽  
Self Reports ◽  
Emdr Therapy

Eye movement desensitization and reprocessing (EMDR) therapy is recognized worldwide as an effective treatment for the symptoms of posttraumatic stress disorder (PTSD) and all kinds of adverse life experiences. The literature on the clinical usefulness of EMDR therapy in people with Alzheimer's disease is scarce. We present a clinical case study of a woman who was recently diagnosed with Alzheimer's disease. This patient was suffering from daily flashbacks of her institutionalized mother in a later stage of dementia. According to self-reports, one session of EMDR therapy alleviated the distress associated with her traumatic memory. We discuss the applicability of the EMDR protocol for people with Alzheimer's disease and highlight possible limitations and adaptations.

Distinct social-behavioral changes in frontotemporal dementia and early onset Alzheimer's disease

2014 ◽  
Author(s):  
Joseph P. Barsuglia ◽  
Michelle J. Mather ◽  
Hemali V. Panchal ◽  
Aditi Joshi ◽  
Elvira Jimenez ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Frontotemporal Dementia ◽  
Early Onset ◽  
Behavioral Changes ◽  
Early Onset Alzheimer’S Disease

Depressive Symptoms and APOE ε2 Broad the Natural History in Presenilin-1 E280A Familial Early-Onset Alzheimer's Disease

2018 ◽  
Author(s):  
Natalia Acosta-Baena ◽  
Carlos Mario Lopera-Gómez ◽  
Mario César Jaramillo-Elorza ◽  
Margarita Giraldo-Chica ◽  
Mauricio Arcos-Burgos ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Depressive Symptoms ◽  
Natural History ◽  
Early Onset ◽  
Presenilin 1 ◽  
Early Onset Alzheimer’S Disease

Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease

2020 ◽  
Vol 21 (12) ◽  
pp. 1164-1173
Author(s):  
Siju Ellickal Narayanan ◽  
Nikhila Sekhar ◽  
Rajalakshmi Ganesan Rajamma ◽  
Akash Marathakam ◽  
Abdullah Al Mamun ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Precursor Protein ◽  
Early Onset ◽  
Late Onset ◽  
Precursor Protein ◽  
Brain Disorder ◽  
Amyloid Aβ ◽  
T Tau

: Alzheimer’s disease (AD) is a progressive brain disorder and one of the most common causes of dementia and death. AD can be of two types; early-onset and late-onset, where late-onset AD occurs sporadically while early-onset AD results from a mutation in any of the three genes that include amyloid precursor protein (APP), presenilin 1 (PSEN 1) and presenilin 2 (PSEN 2). Biologically, AD is defined by the presence of the distinct neuropathological profile that consists of the extracellular β-amyloid (Aβ) deposition in the form of diffuse neuritic plaques, intraneuronal neurofibrillary tangles (NFTs) and neuropil threads; in dystrophic neuritis, consisting of aggregated hyperphosphorylated tau protein. Elevated levels of (Aβ), total tau (t-tau) and phosphorylated tau (ptau) in cerebrospinal fluid (CSF) have become an important biomarker for the identification of this neurodegenerative disease. The aggregation of Aβ peptide derived from amyloid precursor protein initiates a series of events that involve inflammation, tau hyperphosphorylation and its deposition, in addition to synaptic dysfunction and neurodegeneration, ultimately resulting in dementia. The current review focuses on the role of proteomes in the pathogenesis of AD.

Sign in / Sign up

Export Citation Format

Share Document